Nanoliposomes increases Anti-Trichomonas vaginalis and apoptotic activities of metronidazole

Ebrahimi, Mina; Montazeri, Mahbobeh; Ahmadi, Amirhosien; Nami, Sanam; Hamishehkar, Hamed; Shahrivar, Firooz; Bakhtiar, Nayer Mehdizad; Nissapatorn, Veeranoot; Spotin, Adel; Ahmadpour, Ehsan

doi:10.1016/j.actatropica.2021.106156

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors demonstrated, through the analysis of the in vitro trichomonacidal activity of nanoliposomes with a size of 146.8 nm, an IC 50 value of 15.9 µg/mL after 6 h of incubation, while the free-form presented a higher IC 50 value (31.51 µg/mL). Still, 12 h was necessary for the nanolipossomal formulation to lyse T. vaginalis entirely, while MTZ required 24 h to cause this effect [109].…”

Section: Articles: Nanotechnologymentioning

confidence: 99%

Novel Treatment Approaches to Combat Trichomoniasis, a Neglected and Sexually Transmitted Infection Caused by Trichomonas vaginalis: Translational Perspectives

et al. 2022

View full text Add to dashboard Cite

The multistep translational science behind new drugs comprehends the entire process through laboratory, clinical, and community observations turned into health interventions. The development of new drug options from discovering targets and leading compounds in basic research for implementing therapeutic guidelines contributes to the emergence of health policies essential for infection control. This review updates the translational research in the scenario of the most common non-viral sexually transmitted infection (STI), trichomoniasis. Paradoxically to its high occurrence, it is considered neglected since notification is not mandatory. It turns into a stable disease with health complications, and receives little emphasis from public health programs to control STI. Although related to curable STIs, the current drugs, metronidazole and tinidazole, present therapeutic failures. The need for new options to treat trichomoniasis is established by basic research studies and patents revealing novel synthetic compounds and natural products presenting anti-Trichomonas vaginalis activities, mainly based on in vitro findings. Clinical trials are still focused on new routes of administration for conventional drugs. In addition, nanotechnology approaches are in their infancy, shedding light on potential possibilities for creating more effective, targeted, and safe delivery systems. Overall, the novel proposed approaches need, in addition to pharmaceutical development and efficacy assessments, to ensure that the quality requirements for their use as medicines are met. It is essential to overcome these issues to cross the “Death Valley” of drug discovery and to advance in the translational science criteria in the trichomoniasis drug development field.

show abstract

Section: Articles: Nanotechnologymentioning

confidence: 99%

Novel Treatment Approaches to Combat Trichomoniasis, a Neglected and Sexually Transmitted Infection Caused by Trichomonas vaginalis: Translational Perspectives

et al. 2022

View full text Add to dashboard Cite

show abstract

A review on the nanotechnology-based approaches for managing sexually transmitted infections

Zeb,

Khan,

Shah

et al. 2024

J. Pharm. Investig.

View full text Add to dashboard Cite

Nanomaterials as a Potential Target for Infectious Parasitic Agents

Alsharedeh

Rezigue

Bashatwah

et al. 2024

CDD

View full text Add to dashboard Cite

Despite the technological advancement in the era of personalized medicine and therapeutics development, infectious parasitic causative agents remain one of the most challenging areas of research and development. The disadvantages of conventional parasitic prevention and control are the emergence of multiple drug resistance as well as the non-specific targeting of intracellular parasites, which results in high dose concentration needs and subsequently intolerable cytotoxicity. Nanotechnology has attracted extensive interest to reduce medication therapy adverse effects including poor bioavailability and drug selectivity. Numerous nanomaterials-based delivery systems have previously been shown in animal models to be effective in the treatment of various parasitic infections. This review discusses a variety of nanomaterials-based antiparasitic procedures and techniques as well as the processes that allow them to be targeted to different parasitic infections. This review focuses on the key prerequisites for creating novel nanotechnology-based carriers as a potential option in parasite management, specifically in the context of human-related pathogenic parasitic agents.

show abstract

Nanoliposomes increases Anti-Trichomonas vaginalis and apoptotic activities of metronidazole

Cited by 3 publications

References 29 publications

Novel Treatment Approaches to Combat Trichomoniasis, a Neglected and Sexually Transmitted Infection Caused by Trichomonas vaginalis: Translational Perspectives

Novel Treatment Approaches to Combat Trichomoniasis, a Neglected and Sexually Transmitted Infection Caused by Trichomonas vaginalis: Translational Perspectives

A review on the nanotechnology-based approaches for managing sexually transmitted infections

Nanomaterials as a Potential Target for Infectious Parasitic Agents

Contact Info

Product

Resources

About